H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $11 from $9 and keeps a Buy rating on the shares. United Therapeutics (UTHR) announced that Tyvaso Inhalation Solution met its primary efficacy endpoint of demonstrating improvement in absolute forced vital capacity relative to placebo, the analyst tells investors in a research note. The firm says that beyond the upside from the potential additional royalties and cash flow to MannKind, the positive TETON-2 data “removes a significant overhang” on the shares. H.C. Wainwright thinks the stock can now re-rate toward its intrinsic value.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- Unusually active option classes on open September 2nd
- MannKind’s Strategic Collaborations and Innovations Drive Buy Rating Amid Promising IPF Treatment Developments
- Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- MannKind Amends License Agreement with United Therapeutics
- MannKind, United Therapeutics expand collaboration for second inhaled therapy